title: A multicenter comparative study of cefotetan once daily and cefoxitin thrice daily for the treatment of infections of the skin and superficial soft tissue.
abstract: To compare the effectiveness of cefotetan administered at 2 g once a day with cefoxitin at 1 or 2 g three times a day in the treatment of hospitalized patients with skin and superficial soft tissue infections, 194 patients from eight centers were enrolled in an open, randomized trial. Most of the 104 evaluable patients in the cefotetan group and 50 in the cefoxitin group were young men with community-acquired, moderate or severe cellulitis, or abscesses of the upper and lower extremities caused by Staphylococcus aureus, Streptococcus species, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and other species of bacteroides, peptococcus species, and peptostreptococcus species. The mean duration of treatment was 7.5 days for cefotetan and 7.1 days for cefoxitin. A successful clinical response was achieved in 97 percent of the cefotetan patients and in 94 percent of the cefoxitin patients. Of the 88 and 39 bacteriologically evaluable patients in the cefotetan and cefoxitin groups, respectively, a satisfactory bacteriologic response occurred in 96 percent and 87 percent of the patients. No clinically significant changes in clinical laboratory determinations were noted. The incidence of adverse reactions in the cefotetan group (17 percent) was significantly different from that for the cefoxitin group (6 percent) (p less than 0.05); however, the incidence of treatment-related reactions was not significant and the events were mild. Discontinuation of therapy was necessary only in two patients in whom allergic-type reactions developed. A once-daily regimen of cefotetan was as effective as thrice-daily cefoxitin in this study in the treatment of primarily polymicrobial, moderate, or severe infections of the skin and superficial soft tissue.
authors.affiliation: Division of Infectious Diseases, Mercy Hospital, Baltimore, Maryland 21202.
authors.forename: R W
authors.initials: RW
authors.lastname: Geckler
authors.forename: R H
authors.initials: RH
authors.lastname: Eng
authors.forename: T C
authors.initials: TC
authors.lastname: Fabian
authors.forename: R M
authors.initials: RM
authors.lastname: Echols
authors.forename: J G
authors.initials: JG
authors.lastname: Jemsek
authors.forename: J L
authors.initials: JL
authors.lastname: LeFrock
authors.forename: W C
authors.initials: WC
authors.lastname: Mogabgab
authors.forename: S E
authors.initials: SE
authors.lastname: Wilson
mesh_terms: D000038:Abscess / Q000188:drug therapy*; D000328:Adult; D015313:Cefotetan; D002440:Cefoxitin / Q000008:administration & dosage* / Q000627:therapeutic use; D002481:Cellulitis / Q000188:drug therapy*; D002513:Cephamycins / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation; D012874:Skin Diseases, Infectious / Q000188:drug therapy*
chemical_list: D002513:Cephamycins; D015313:Cefotetan; D002440:Cefoxitin